Popular filter options for idiopathic pulmonary fibrosis trials
IPF Clinical Trials
View 41 IPF medical studies.
Oral ORIN1001 for Idiopathic Pulmonary Fibrosis
This trial is testing a new drug, ORIN1001, to see if it is safe and effective in treating adults with idiopathic pulmonary fibrosis (IPF). The trial will have 3 groups of 8 people, who will either receive the new drug or a placebo. The trial will last 28 days.
PET/CT Imaging for Idiopathic Pulmonary Fibrosis
This trial is testing if two different imaging techniques can show evidence of lung inflammation and fibrosis in patients with idiopathic pulmonary fibrosis. The results may help guide future treatment decisions for patients with this condition.
Mucolytic Agent
N-acetyl Cysteine for Idiopathic Pulmonary Fibrosis
This trial will compare the effect of NAC plus standard care with placebo plus standard of care in patients with idiopathic pulmonary fibrosis who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function, first respiratory hospitalization, lung transplantation, or all-cause mortality.
Xenon MRI for Idiopathic Pulmonary Fibrosis
This trial is being done to see if MRI using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments.
NADPH Oxidase Inhibitor
GKT137831 for Idiopathic Pulmonary Fibrosis
This trial is testing a new drug, GKT137831, to see if it can help treat idiopathic pulmonary fibrosis (IPF), a lung disease that until now has had no good treatment options. The drug works by inhibiting an enzyme that produces reactive oxygen species (ROS), which are thought to play a role in the development of IPF. If the drug is effective, it could represent a major breakthrough for IPF patients.
Phase 3 Idiopathic Pulmonary Fibrosis Clinical Trials
View 43 phase 3 idiopathic pulmonary fibrosis medical studies.
Mucolytic Agent
N-acetyl Cysteine for Idiopathic Pulmonary Fibrosis
This trial will compare the effect of NAC plus standard care with placebo plus standard of care in patients with idiopathic pulmonary fibrosis who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function, first respiratory hospitalization, lung transplantation, or all-cause mortality.
Procedure
Sodium Pyruvate Nasal Spray for Idiopathic Pulmonary Fibrosis
This trial will test a nasal spray to reduce coughing and improve lung function in patients with idiopathic pulmonary fibrosis. Results will be measured over 21 days in a double-blind, placebo-controlled trial.
Idiopathic Pulmonary Fibrosis Clinical Trials With No Placebo
View 43 idiopathic pulmonary fibrosis medical studies that do not have a placebo group.
PET/CT Imaging for Idiopathic Pulmonary Fibrosis
This trial is testing if two different imaging techniques can show evidence of lung inflammation and fibrosis in patients with idiopathic pulmonary fibrosis. The results may help guide future treatment decisions for patients with this condition.
Xenon MRI for Idiopathic Pulmonary Fibrosis
This trial is being done to see if MRI using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments.
View More Idiopathic Pulmonary Fibrosis Trials
See another 20 medical studies focused on idiopathic pulmonary fibrosis.
Frequently Asked Questions
Introduction to idiopathic pulmonary fibrosis
What are the top hospitals conducting idiopathic pulmonary fibrosis research?
In the battle against idiopathic pulmonary fibrosis (IPF), several hospitals are leading the charge in groundbreaking clinical trials. Winston-Salem's Southeastern Research Center takes a prominent position with 10 active IPF trials and a cumulative total of 11 trials dedicated to this enigmatic disease. Their efforts date back to their first recorded trial in 2020, demonstrating their commitment to advancing our understanding of IPF. Meanwhile, the University of Kansas Medical Center in Kansas City has made significant strides as well, currently conducting six active IPF trials and boasting a history of 14 completed studies since their initial trial in 2013.
Notably, Massachusetts General Hospital in Boston has also emerged as a key player on the forefront of IPF research. With five ongoing clinical trials focused on this condition and an impressive track record of 16 previous investigations dating back to their inaugural study in 2011, they exemplify dedication towards unraveling the complexities surrounding IPF. Vanderbilt University Medical Center located in Nashville has been at the vanguard too, actively engaging in five current IPF clinical trials while contributing significantly with twenty-five accomplished studies since initiating its pioneering investigation into this condition back in 2003.
Even smaller-scale institutions like Franklin's Clinical Trials Center of Middle Tennessee play an important role by dedicating themselves to advancing knowledge about IPF through five ongoing clinical trials and making valuable contributions with a cumulative total of five completed investigations thus far; theirs being traced only until recently recording their first trial solely focused on IDP last yearin2021.
These esteemed hospitals represent beacons hope for those affected by idiopathic pulmonary fibrosis by actively pursuing novel treatment approaches through cutting-edge clinical research. Each step forward brings us closer to unraveling the mysteries behind this debilitating condition that affects thousands across the nation."
Which are the best cities for idiopathic pulmonary fibrosis clinical trials?
When it comes to idiopathic pulmonary fibrosis clinical trials, several cities stand out as hubs of research and development. Philadelphia, Pennsylvania leads the way with 17 active trials investigating treatments like Inhaled Treprostinil, HZN-825, and BMS-986278 Dose 1. Los Angeles, California also boasts 17 ongoing studies examining interventions such as N-acetyl cysteine and LTI-03 BID. Additionally, Dallas, Texas offers 15 active trials exploring options like CSL312 and Inhaled Treprostinil. These cities are joined by Birmingham, Alabama with 14 trials and Winston-Salem, North carolina with 11 trials focused on advancing our understanding and treatment of idiopathic pulmonary fibrosis through cutting-edge clinical research efforts.
Which are the top treatments for idiopathic pulmonary fibrosis being explored in clinical trials?
Exciting developments are underway in the realm of idiopathic pulmonary fibrosis (IPF) treatments, as clinical trials explore potential breakthroughs. Inhaled treprostinil has emerged as a frontrunner, with two ongoing trials dedicated to IPF and three all-time trials since its introduction in 2021. Another promising contender is INS018_055, currently being evaluated in two active IPF trials after its debut on the scene in 2022. Additionally, PLN-74809 shows promise with one active trial and three all-time IPF trials since its listing in 2019. These innovative therapies hold great hope for patients battling this challenging condition—a glimmer of light amidst the darkness of IPF.
What are the most recent clinical trials for idiopathic pulmonary fibrosis?
Recent clinical trials offer hope for patients with idiopathic pulmonary fibrosis, a debilitating lung condition. One such trial is investigating the effectiveness of BMS-986278 in treating this disease. This Phase 3 study became available on 9/14/2023 and aims to evaluate the potential benefits of this new therapy. Another promising trial involves Leramistat, which is being studied in a Phase 2 trial that became available on 8/30/2023. Additionally, a Phase 1 trial exploring the combination of EGCG and Pirfenidone has shown promise as a potential treatment option for idiopathic pulmonary fibrosis patients. These recent advancements bring renewed optimism for individuals battling this challenging condition.
What idiopathic pulmonary fibrosis clinical trials were recently completed?
In recent years, a number of clinical trials have been completed in the pursuit of improved treatments for idiopathic pulmonary fibrosis (IPF). Notably, AstraZeneca successfully concluded their trial investigating AZD5055 in November 2021. Similarly, Pliant Therapeutics wrapped up their trial evaluating PLN-74809 in March 2020. Other notable completed trials include NIP292 tablets conducted by The National Institutes of Pharmaceutical R&D Co. Ltd (China) in November 2019 and GB0139 by Galecto Biotech AB in February 2019. While these studies represent important milestones, it is crucial to continue advancing research efforts to address the challenges posed by IPF and offer hope to patients affected by this debilitating condition.